$30.2M
in disclosed stock, +$200K (+0.67%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
- Rank
- 3762nd of 14,644
- Companies held
- 1
- Largest holding
- CGEM, 100.0% of total
- Latest SEC filing
- May 16, 2022
What the $30.2M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Cullinan Therapeutics CGEM Common Stock | Directly | 1,305,873 | $9.07 | $11.8M | 39.2% | Form 4, May 16, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through F2 Bioscience I 2017 Ltd. | 639,295 | $9.07 | $5.8M | 19.2% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through Globeways Holdings Ltd. Reported jointly by 2 insiders; split evenly | 568,263 | $9.07 | $5.2M | 17.1% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through F2-TPO Investments, LLC Reported jointly by 2 insiders; split evenly | 311,088 | $9.07 | $2.8M | 9.3% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through F2 MG Ltd. Reported jointly by 2 insiders; split evenly | 162,667 | $9.07 | $1.5M | 4.9% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through Morana Jovan-Embiricos | 112,507 | $9.07 | $1.0M | 3.4% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through F2 MC, LLC Reported jointly by 2 insiders; split evenly | 107,399 | $9.07 | $974K | 3.2% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through F2 Bio TD, LLC | 71,599 | $9.07 | $649K | 2.1% | Form 4, May 12, 2022 |
| Cullinan Therapeutics CGEM Common Stock | Through F2 GC, LLC Reported jointly by 2 insiders; split evenly | 52,381 | $9.07 | $475K | 1.6% | Form 4, May 12, 2022 |
Share counts are the amounts Vision Scs F2 reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 3759 | Shelley Simpson President and CEO, J.B. Hunt Transport Services. Lowell, AR | $30.2M |
| 3760 | Michael Koehnen Director, TriCo Bancshares. Chico, CA | $30.2M |
| 3761 | Larry Wood Global President TAVR & Surg, Edwards Lifesciences. San Jose, CA | $30.2M |
| 3762 | Vision Scs F2 10% owner, Cullinan Therapeutics | $30.2M |
| 3763 | David Slater Exec. Chair and CEO, DT Midstream. Detroit, MI | $30.2M |
| 3764 | Johnny Trotter Director, First Financial Bankshares. Abilene, TX | $30.2M |
| 3765 | Seth Demsey Co-Chief Executive Officer, Corvex. Arlington, VA | $30.2M |
Other Cullinan Therapeutics insiders
All CGEM insiders- Morana Jovan-Embiricos$29.7M10% owner. #3730 overall
- Ansbert Gadicke$5.4M10% owner. #13294 overall
Questions
How much stock does Vision Scs F2 own?
Vision Scs F2 holds $30,212,809 in listed stock based on SEC filings and current prices, mostly Cullinan Therapeutics (CGEM). That ranks 3762nd on the Stock Rich List.
Is this Vision Scs F2's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
Files jointly with Morana Jovan-Embiricos.